How ibogaine and ketamine compare for addiction — legality, opioid and alcohol evidence, cardiac risk, session length, access, and cost.
The choice of ibogaine vs ketamine for addiction comes down to a hard trade-off: power versus safety and access. Ibogaine shows the strongest psychedelic signal for opioid use disorder, yet it carries serious heart risk and is not legal in the United States. Ketamine is legal, widely available, and well studied for depression. This guide compares both drugs side by side so you can see which path fits your situation today.
Ibogaine has the most striking results for opioid use disorder. People often report that one long session resets cravings and eases withdrawal. But it is Schedule I, not FDA-approved, and can stop the heart. Ketamine is legal in all 50 states and much safer, though its addiction evidence is thinner and focused on alcohol, not opioids. For most people in the US today, ketamine is the only legal, monitored option you can actually access.
| Factor | Ibogaine | Ketamine |
|---|---|---|
| Legal status (US) | Schedule I. Not FDA-approved. Legal access only via international clinics or FDA-authorized (IND) trials. | Schedule III. Legal nationwide. Esketamine (Spravato) is FDA-approved for depression. |
| What it treats | Studied mainly for opioid use disorder, plus PTSD and TBI in veterans. | FDA-approved for treatment-resistant depression; off-label use and addiction research too. |
| How it works | Acts on many receptors at once (opioid, serotonin, NMDA, others). Resets withdrawal in one dose. | Blocks the NMDA glutamate receptor; a dissociative that sparks new brain connections. |
| Evidence for addiction | Strongest psychedelic signal for opioids, but mostly small or early-stage studies. | Promising trial data for alcohol use disorder (KARE); little opioid-specific data. |
| Safety / cardiac risk | Serious. Prolongs the QT interval; deaths have occurred. Needs continuous heart monitoring. | Generally safe under supervision. Risks include high blood pressure, bladder harm, and misuse. |
| Session length | One intense 24–36 hour experience, with days of recovery after. | 40–60 minutes per session; a full course is often 6 or more sessions. |
| Where to access / cost | Mexico and other clinics abroad, often $6,000–$10,000+. US only through trials. | Clinics and telehealth nationwide; ~$150–$800 per session. |
Ibogaine is unusual. It acts on many brain systems at once, including opioid, serotonin, and NMDA receptors. People with opioid addiction often report that a single high dose quickly eases withdrawal and quiets cravings. Our full ibogaine guide explains the science and the risks in detail.
Ketamine works mainly by blocking the NMDA glutamate receptor. This sets off a burst of new brain connections that many researchers link to its fast antidepressant effect. It is a dissociative, not a classic psychedelic. Our ketamine guide covers how it is used in clinics today. The two drugs feel and act very differently.
Ibogaine has the strongest psychedelic signal for opioid addiction. In 2024, a Stanford study (the MISTIC protocol) gave ibogaine with magnesium to 30 Special Operations veterans and reported large drops in PTSD, anxiety, and depression.1 In 2025, Texas approved a $50 million consortium (IMPACT) to run FDA-track ibogaine trials for addiction, PTSD, and TBI.2 Still, most ibogaine evidence comes from small studies and clinic reports, not large controlled trials.
Ketamine's addiction data is best for alcohol. In the UK KARE trial, people who got low-dose ketamine plus therapy stayed sober for about 87% of the six-month follow-up.3 A larger Phase 3 trial (MORE-KARE) is now running across UK sites. But ketamine is not FDA-approved for any addiction, and strong opioid-specific data is limited.
Safety is the single biggest difference between these two drugs. Ibogaine can be deadly. Ketamine, under supervision, is far safer.
Ketamine carries lighter risks. It can raise blood pressure and heart rate, and heavy long-term use can harm the bladder. It also has some misuse potential. But serious harm is rare when a trained provider runs the session. This safety gap is why access rules for the two drugs differ so much.
Ketamine is Schedule III. Doctors can prescribe it anywhere in the US, and esketamine (Spravato) is FDA-approved for treatment-resistant depression. Ibogaine is Schedule I and has no FDA approval. The only legal US access is through FDA-authorized clinical trials, like the new Texas program. Many people travel to clinics in Mexico, where ibogaine is not banned.
To see how your state treats each drug, check our guide on what psychedelics are legal in the US. Not sure which substance even matches your goals? Try our which psychedelic quiz for a starting point.
Lean toward ibogaine if your main problem is opioid addiction, other treatments have failed, and you can reach a licensed clinic or trial with full cardiac monitoring. Its single-session reset of opioid withdrawal is unique. But never pursue it outside a medically supervised, heart-monitored setting.
Lean toward ketamine if you want a legal, available option now, need a safer profile, or your struggle involves alcohol plus depression. It is the only one of the two you can legally access in the US today. For most people, that access and safety gap decides the question.
Ibogaine vs ketamine is really a choice between a powerful but risky frontier treatment and a safer, proven one you can get right now. Talk with a qualified clinician before acting on either.
It depends on the addiction. Ibogaine has the strongest psychedelic signal for opioid use disorder, since one session can ease withdrawal and cravings. Ketamine has better data for alcohol use disorder and is much safer and easier to access. Ibogaine is more powerful for opioids but carries serious heart risk and is not legal in the US, while ketamine is legal nationwide.
No. Ibogaine is a Schedule I drug and has no FDA approval. The only legal US access is through FDA-authorized clinical trials, such as the Texas IMPACT consortium funded in 2025. Many people travel to clinics in countries like Mexico, where ibogaine is not banned. Ketamine, by contrast, is Schedule III and legal across all 50 states.
Ibogaine has the more striking reputation for opioid withdrawal. People often report that a single high dose sharply reduces withdrawal symptoms and cravings within a day. Ketamine is not a standard opioid-withdrawal treatment and has little opioid-specific evidence. However, ibogaine must only be used with continuous cardiac monitoring because it can cause fatal heart rhythm problems.
Ibogaine is far more dangerous. It blocks a key heart channel and prolongs the QT interval, which can trigger deadly arrhythmias. A published review linked at least 19 deaths to ibogaine, many during opioid detox, so it requires an ECG and emergency care on hand. Ketamine is generally safe under supervision, with lighter risks like raised blood pressure, dissociation, and bladder harm from heavy long-term use.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.